RESUMEN
Two series of new aromatic thiosemicarbazone derivatives were synthesized by condensation of N-(4-cyanophenyl)hydrazine carbothioamide (I) and N-(4-methylsulfanylphenyl)hydrazine carbothioamide (II) with appropriate aromatic aldehydes in order to investigate their antiviral and cytostatic potency. The chemical structures of all compounds were fully characterized by elemental analysis and spectroscopic techniques. The results of the bioassays indicated that compounds Id, Ie, If and IIf proved inhibitory against influenza virus A (EC50 = 13 - 27 µg/mL for strain H1N1 and 9.3 - 18 µg/mL for strain H3N2). Compounds Ig and IIg were the most cytostatic compounds with inhibition of HeLa cell proliferation at an IC50 = 0.3 µg/mL for Ig and 1.9 µg/mL for IIg. Especially, compound Ig showed the highest cytostatic activity with IC50 of 0.30, 0.70 and 2.50 µg/mL against HeLa, CEM and L1210 cell lines, respectively. This inhibition range was within the same order of magnitude as that for cisplatin. Furthermore, molecular modeling was carried out to examine the cytostatic activity and determine the best pharmacophore model as a guide for the design and development of potential prodrugs in future studies.
RESUMEN
The bio-reversible protection of nucleoside diphosphates is summarized. The design, hydrolytic characteristics, and the antiviral activity of these prodrugs of NDPs are described. In contrast to earlier attempts, the DiPPro-approach [ß-(bis(acyloxybenzyl) nucleoside diphosphates)] leads to the successful delivery of the desired nucleoside diphosphates. The stability towards hydrolysis is dependent on the specific acyl moieties in the bis(acyloxybenzyl) unit as well as on the particular nucleoside analogue. Hydrolysis studies in aqueous PBS buffer (pH 7.3), 20 % human plasma in PBS, RPMI-1640 culture medium, and CEM cell extracts were carried out. Contrary to a high chemical and plasma stability, the compounds showed a very low half-life in CEM cell extracts, and efficiently released the nucleoside analogues diphosphates, e.g. of AZT, d4T and BVDU. Two additional types of cycloSal- NDP prodrugs were studied but neither proved to be useful as nucleoside diphosphate prodrugs. In summary, the results led to the development of a new series of non-symmetric nucleoside diphosphate prodrugs that selectively delivered the nucleoside diphosphate in cell extracts.
Asunto(s)
Fármacos Anti-VIH/química , Nucleósidos/química , Profármacos/química , Animales , Fármacos Anti-VIH/metabolismo , Fármacos Anti-VIH/toxicidad , Proliferación Celular/efectos de los fármacos , Difosfatos/química , Esterasas/metabolismo , VIH-1/efectos de los fármacos , VIH-2/efectos de los fármacos , Humanos , Nucleósidos/metabolismo , Nucleósidos/toxicidad , Profármacos/metabolismo , Profármacos/toxicidadRESUMEN
The aqueous extraction of the sesquiterpene lactone xanthatin from Xanthium spinosum L. favours the conversion of xanthinin (1) to xanthatin (2) via the loss of acetic acid. The cytotoxic (Hep-G2 and L1210 human cell lines) and antiviral activities of isolated xanthatin are established. This natural compound shows significant cytotoxicity against the Hep-G2 cell line and our experimental results reveal its strong anti-angiogenesis capacity in vitro. The structure of xanthatin is determined by spectroscopic methods and for the first time confirmed by X-ray diffraction.
Asunto(s)
Inhibidores de la Angiogénesis/farmacología , Antineoplásicos Fitogénicos/farmacología , Antivirales/farmacología , Furanos/farmacología , Neovascularización Patológica/tratamiento farmacológico , Virus/efectos de los fármacos , Xanthium/química , Inhibidores de la Angiogénesis/química , Inhibidores de la Angiogénesis/aislamiento & purificación , Animales , Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/aislamiento & purificación , Antivirales/química , Antivirales/aislamiento & purificación , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Furanos/química , Furanos/aislamiento & purificación , Células Hep G2 , Humanos , Ratones , Pruebas de Sensibilidad Microbiana , Conformación Molecular , Ratas , Relación Estructura-Actividad , Células Tumorales CultivadasRESUMEN
Mycoplasmas are opportunistic parasites and some species are suggested to preferentially colonize tumor tissue in cancer patients. We could demonstrate that the annotated thymidine phosphorylase (TP) gene in the genome of Mycoplasma hyorhinis encodes a pyrimidine nucleoside phosphorylase (PyNPHyor) that not only efficiently catalyzes thymidine but also uridine phosphorolysis. The kinetic characteristics of PyNPHyor-catalyzed nucleoside and nucleoside analogue (NA) phosphorolysis were determined. We demonstrated that the expression of such an enzyme in mycoplasma-infected cell cultures dramatically alters the activity of various anticancer/antiviral NAs such as 5-halogenated pyrimidine nucleosides, including 5-trifluorothymidine (TFT). Due to their close association with human cancers, the presence of mycoplasmas may markedly influence the therapeutic efficiency of nucleoside-based drugs.
Asunto(s)
Antivirales/farmacología , Mycoplasma hyorhinis/enzimología , Pirimidina Fosforilasas/metabolismo , Trifluridina/farmacología , Línea Celular Tumoral , Humanos , Células MCF-7 , Mycoplasma hyorhinis/fisiología , Pirimidina Fosforilasas/genéticaRESUMEN
Cytostatic agents often do not discriminate in their cytostatic potential between different tumor cell types in vitro. In this study, several 2-aminothiophene-3-carboxylic acid ester derivatives were discovered that show an unusual cytostatic selectivity for several T-cell (but not B-cell) lymphoma, prostate cancer, kidney carcinoma and hepatoma cell lines. Their 50 % cytostatic concentrations were generally in the higher nanomolar range and were approximately 20- to 50-fold lower for these tumor cell types than for any other tumor cell line or non-tumorigenic cells. The tumor-selective compounds caused a more preferential suppression of protein synthesis than DNA or RNA synthesis and the prototype compound 3 resulted in an accumulation of prostate cancer cells in the G1 phase of their cell cycle. Compound 3 was also shown to induce apoptosis in prostate cancer cells. The 2-aminothiophene-3-carboxylic acid ester derivatives represent novel candidate cytostatic agents to be further explored for their tumor-selective potential.
Asunto(s)
Aminoácidos/uso terapéutico , Citostáticos/uso terapéutico , Ésteres/uso terapéutico , Tiofenos/uso terapéutico , Aminoácidos/química , Apoptosis/efectos de los fármacos , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Citostáticos/química , Ésteres/química , Humanos , Neoplasias/tratamiento farmacológico , Neoplasias/patología , Relación Estructura-Actividad , Tiofenos/químicaRESUMEN
Ethyl 5-hydroxy-1-methyl-2-(trans-2-phenylcyclopropyl)-1H-indole-3-carboxylate is the first prototype of conformationally restricted analogs of umifenovir. It has been prepared using a one-pot method and has undergone an antiviral study.
RESUMEN
A novel nucleoside analogue, 1-[(2S,4S-2-(hydroxymethyl)-1,3-dioxolan-4-yl]5-vinylpyrimidine-2,4(1H,3H)-dione, or HDVD, was evaluated against a wide variety of herpesviruses and was found to be a highly selective inhibitor of replication of the gammaherpesviruses Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV). HDVD had also a pronounced inhibitory activity against murine herpesvirus 68 (MHV-68) and herpes simplex virus 1 (HSV-1). In contrast, replication of herpesvirus saimiri (HVS), HSV-2, and varicella-zoster virus (VZV) was weakly inhibited by the compound, and no antiviral activity was determined against human cytomegalovirus (HCMV) and rhesus rhadinovirus (RRV). The HDVD-resistant virus phenotype contained point mutations in the viral thymidine kinase (TK) of HSV-1, MHV-68, and HVS isolates. These mutations conferred cross-resistance to other TK-dependent drugs, with the exception of an MHV-68 mutant (E358D) that exhibited resistance only to HDVD. HSV-1 and HVS TK-mutants isolated under selective pressure with bromovinyldeoxyuridine (BVDU) also showed reduced sensitivity to HDVD. Oral treatment with HDVD and BVDU was assessed in an intranasal model of MHV-68 infection in BALB/c mice. In contrast to BVDU treatment, HDVD-treated animals showed a reduction in viral DNA loads and diminished viral gene expression during acute viral replication in the lungs in comparison to levels in untreated controls. The valyl ester prodrug of HDVD (USS-02-71-44) suppressed the latent infection in the spleen to a greater extent than HDVD. In the present study, HDVD emerged as a highly potent antiviral with a unique spectrum of activity against herpesviruses, in particular, gammaherpesviruses, and may be of interest in the treatment of virus-associated diseases.
Asunto(s)
Antivirales/farmacología , Gammaherpesvirinae/efectos de los fármacos , Nucleósidos/farmacología , Nucleósidos de Pirimidina/farmacología , Pirimidinas/farmacología , Replicación Viral/efectos de los fármacos , Animales , Antivirales/metabolismo , Aotidae , Cartilla de ADN/genética , Fibroblastos , Gammaherpesvirinae/genética , Humanos , Macaca mulatta , Ratones , Ratones Endogámicos BALB C , Estructura Molecular , Mutación/genética , Células 3T3 NIH , Nucleósidos/química , Nucleósidos/metabolismo , Nucleósidos de Pirimidina/metabolismo , Pirimidinas/química , Pirimidinas/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Rhadinovirus/efectos de los fármacos , Especificidad de la Especie , Estadísticas no Paramétricas , Timidina Quinasa/genéticaRESUMEN
BACKGROUND: Bicyclam derivatives inhibit feline immunodeficiency virus (FIV) replication through selective blockage of chemokine receptor CXCR4. HYPOTHESIS/OBJECTIVES: CXCR4 antagonist plerixafor (AMD3100, 1,1'-bis-1,4,8,11-tetraazacyclotetradekan) alone or combination with adefovir (PMEA, 9-(2-phosphonylmethoxyethyl)adenine) safe and effective for treating FIV-infected cats. ANIMALS: Forty naturally FIV-infected, privately owned cats. MATERIALS AND METHODS: Prospective, placebo-controlled, double-blind clinical trial. Cats randomly classified into 4 treatment groups. Received AMD3100, PMEA, AMD3100 in combination with PMEA, or placebo for 6 weeks. Clinical and laboratory parameters, including CD4(+) and CD8(+) cell counts, FIV proviral and viral load measured by quantitative polymerase chain reaction (qPCR) evaluated. Additionally, FIV isolates from cats treated with AMD3100 tested for drug resistance. RESULTS: FIV-infected cats treated with AMD3100 caused significant decrease in proviral load compared to placebo group (2.3 ± 3.8% to 1.9 ± 3.1%, of blood lymphocytes P < .05), but did not lead to improvement of clinical or immunological variables; it caused a decrease in serum magnesium concentration without clinical signs. No development of resistance of FIV isolates to AMD3100 found during treatment period. PMEA administration improved stomatitis (stomatitis score [degree 1 - 100] PMEA group: 23 ± 19 to 11 ± 10, P < .001; AMD3100 + PMEA group: 12 ± 17 to 3 ± 5, P < .05), but did not decrease proviral or viral load and caused anemia (RBC [× 10(6) /µL] PMEA group: 9.07 ± 1.60 to 6.22 ± 2.16, P < .05; AMD3100 ± PMEA group: 8.80 ± 1.23 to 5.84 ± 1.58, P < .001). CONCLUSIONS AND CLINICAL IMPORTANCE: Administration of CXCR4 antagonists, as AMD3100, can induce reduction of proviral load and may represent viable treatment of FIV-infected cats. Combination treatment with PMEA not recommended.
Asunto(s)
Adenina/análogos & derivados , Fármacos Anti-VIH/uso terapéutico , Síndrome de Inmunodeficiencia Adquirida del Felino/tratamiento farmacológico , Compuestos Heterocíclicos/uso terapéutico , Virus de la Inmunodeficiencia Felina/fisiología , Organofosfonatos/uso terapéutico , Adenina/uso terapéutico , Animales , Bencilaminas , Recuento de Células Sanguíneas/veterinaria , Gatos , Ciclamas , Método Doble Ciego , Quimioterapia Combinada/veterinaria , Síndrome de Inmunodeficiencia Adquirida del Felino/virología , Femenino , Masculino , Estudios Prospectivos , Receptores CXCR4/antagonistas & inhibidores , Estadísticas no Paramétricas , Carga Viral/veterinaria , Replicación Viral/efectos de los fármacosRESUMEN
The novel 1-acyl-4-cycloalkyl/arylsemicarbazides (5a-y) and 1-acyl-5-benzyloxy/hydroxycarbamoylcarbazides (8a-f) derived from the nonsteroidal anti-inflammatory drugs ibuprofen, fenoprofen and reduced ketoprofen were prepared, fully chemically characterized and evaluated for their cytostatic, antiviral and antioxidant activities. Compounds 5 and 8 consist of a region rich in electronegative atoms (five to nine nitrogen and oxygen atoms) framed by aryl or cycloalkyl residues on one or both terminal ends. The synthetic pathways applied for the preparation of the title compounds involved a benzotriazole as a synthetic auxiliary in several steps. Three of the tested compounds, namely 4-benzhydryl-1-[2-(3-phenoxyphenyl)propanoyl]semicarbazide (5l), 4-benzhydryl-1-[2-(3-benzylphenyl)propanoyl]semicarbazide (5s), and 4-benzhydryl-1-[2-(4-isobutylphenyl)propanoyl]semicarbazide (5f) showed pronounced antiproliferative activity in vitro against six cancer cell lines (IC(50)=3-23 µM). The same compounds highly inhibited soybean lipoxygenase (IC(50)=60 and 51.5 µM) and lipid peroxidation as well (99, 88 and 74%, respectively). 4-Benzyloxy-1-[2-(4-isobutylphenyl)propanoyl]semicarbazide (5t) and 5-benzyloxycarbamoyl-1-[2-(3-benzylphenyl)propanoyl]carbazide (8c) exerted complete lipid peroxidation inhibition. Semicarbazides 5w-y and carbazides 8d-f bearing a hydroxamic acid/hydroxyurea moiety showed a modest antiradical activity in DPPH test, while the best radical scavenger was 1-(1-benzotriazolecarbonyl)-4-benzyloxysemicarbazide (7). None of the compounds were inhibitory to a broad panel of DNA and RNA viruses in the cell culture at subtoxic concentrations.
Asunto(s)
Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/farmacología , Semicarbacidas/química , Semicarbacidas/farmacología , Antineoplásicos/química , Antineoplásicos/farmacología , Antivirales/química , Antivirales/farmacología , Proliferación Celular/efectos de los fármacos , Depuradores de Radicales Libres/química , Depuradores de Radicales Libres/farmacología , Interacciones Hidrofóbicas e Hidrofílicas , Concentración 50 Inhibidora , Virus/efectos de los fármacosRESUMEN
Twenty-seven years after the discovery of HIV as the cause of AIDS more than 25 drugs directed against four different viral targets (i.e. reverse transcriptase, protease, integrase, envelope gp41) and one cellular target (i.e. CCR5 co-receptor) are available for treatment. However, the search for an efficient vaccine is still ongoing. One of the main problems is the presence of a continuously evolving dense carbohydrate shield, consisting of N-linked glycans that surrounds the virion and protects it against efficient recognition and persistent neutralization by the immune system. However, several lectins from the innate immune system specifically bind to these glycans in an attempt to process the virus antigens to provoke an immune response. Across a wide variety of different species in nature lectins can be found that can interact with the glycosylated envelope of HIV-1 and can block the infection of susceptible cells by the virus. In this review, we will give an overview of the lectins from non-mammalian origin that are endowed with antiviral properties and discuss the complex interactions between lectins of the innate immune system and HIV-1. Also, attention will be given to different carbohydrate-related modalities that can be exploited for antiviral chemotherapy.
Asunto(s)
Antivirales/uso terapéutico , Proteínas Bacterianas/uso terapéutico , Proteínas Portadoras/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/inmunología , VIH-1/inmunología , VIH-1/metabolismo , Humanos , Inmunidad Innata , Lectinas/uso terapéutico , Receptores de Superficie Celular/uso terapéutico , Proteínas del Envoltorio Viral/efectos de los fármacosRESUMEN
Varicella zoster virus (VZV) is usually associated with mild to moderate illness in immunocompetent patients. However, older age and immune deficiency are the most important risk factors linked with virus reactivation and severe complications. Treatment of VZV infections is based on nucleoside analogues, such as acyclovir (ACV) and its valyl prodrug valacyclovir, penciclovir (PCV) as its prodrug famciclovir, and bromovinyldeoxyuridine (BVDU; brivudin) in some areas. The use of the pyrophosphate analogue foscarnet (PFA) is restricted to ACV-resistant (ACV(r)) VZV infections. Since antiviral drug resistance is an emerging problem, we attempt to describe the contributions of specific mutations in the viral thymidine kinase (TK) gene identified following selection with ACV, BVDU and its derivative BVaraU (sorivudine), and the bicyclic pyrimidine nucleoside analogues (BCNAs), a new class of potent and specific anti-VZV agents. The string of 6 Cs at nucleotides 493 to 498 of the VZV TK gene appeared to function as a hot spot for nucleotide insertions or deletions. Novel amino acid substitutions (G24R and T86A) in VZV TK were also linked to drug resistance. Six mutations were identified in the "palm domain" of VZV DNA polymerase in viruses selected for resistance to PFA, PCV, and the 2-phophonylmethoxyethyl (PME) purine derivatives. The investigation of the contributions of specific mutations in VZV TK or DNA polymerase to antiviral drug resistance and their impacts on the structures of the viral proteins indicated specific patterns of cross-resistance and highlighted important differences, not only between distinct classes of antivirals, but also between ACV and PCV.
Asunto(s)
Antivirales/farmacología , ADN Polimerasa Dirigida por ADN/genética , Farmacorresistencia Viral , Herpesvirus Humano 3/enzimología , Mutación/efectos de los fármacos , Nucleósidos/farmacología , Timidina Quinasa/genética , Proteínas Virales/genética , Secuencia de Aminoácidos , Línea Celular , ADN Polimerasa Dirigida por ADN/química , ADN Polimerasa Dirigida por ADN/metabolismo , Evaluación Preclínica de Medicamentos , Genotipo , Infecciones por Herpesviridae/virología , Herpesvirus Humano 3/química , Herpesvirus Humano 3/efectos de los fármacos , Herpesvirus Humano 3/genética , Humanos , Modelos Moleculares , Datos de Secuencia Molecular , Fenotipo , Alineación de Secuencia , Timidina Quinasa/química , Timidina Quinasa/metabolismo , Proteínas Virales/metabolismoRESUMEN
It has been revealed for the first time that sodium fullerenolate Na(4)[C(60)(OH)(â¼30)] (NaFL), a water soluble polyhydroxylated [60]fullerene derivative, destroys amyloid fibrils of the Aß(1-42) peptide in the brain and prevents their formation in in vitro experiments. The cytotoxicity of NaFL was found to be negligibly low with respect to nine different culture cell lines. At the same time, NaFL showed a very low acute toxicity in vivo. The maximal tolerable dose (MTD) and LD50 for NaFL correspond to 1000 mg kg(-1) and 1800 mg kg(-1), respectively, as revealed by in vivo tests in mice using intraperitoneal drug injection. The observed pronounced anti-amyloid activity and low toxicity of NaFL make it a very promising lead drug for the development of potent fullerene-based therapeutic approaches for the treatment of amyloidoses, such as Alzheimer's disease and others.
Asunto(s)
Péptidos beta-Amiloides/antagonistas & inhibidores , Péptidos beta-Amiloides/metabolismo , Fulerenos/química , Fulerenos/farmacología , Fragmentos de Péptidos/antagonistas & inhibidores , Fragmentos de Péptidos/metabolismo , Enfermedad de Alzheimer/tratamiento farmacológico , Amiloidosis/tratamiento farmacológico , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Línea Celular , Supervivencia Celular/efectos de los fármacos , Fulerenos/toxicidad , Humanos , RatonesRESUMEN
Curcumin bioconjugates, viz. di-O-tryptophanylphenylalanine curcumin (2), di-O-decanoyl curcumin (3), di-O-pamitoyl curcumin (4), di-O-bis-(gamma,gamma)folyl curcumin (6), C(4)-ethyl-O-gamma-folyl curcumin (8) and 4-O-ethyl-O-gamma-folyl curcumin (10) have been synthesized and tested for their antibacterial and antiviral activities. The conjugates 2, 3, 4, 6 and 8 have shown very promising antibacterial activity with MIC ranging between 0.09 and 0.67 microM against Gram-positive cocci and Gram-negative bacilli. Further, the conjugates 2, 3, 6, 8 and 10 have been screened for their antiviral activities against HSV, VSV, FIPV, PIV-3, RSV and FHV and the molecules 2 and 3 have shown good results with EC(50) 0.011 microM and 0.029 microM against VSV and FIPV/FHV, respectively. However, the molecules did not show expected results against HIV-1 III(B) and ROD strains in MTT assay.
Asunto(s)
Antibacterianos , Antivirales , Bacterias/efectos de los fármacos , Curcumina , Dipéptidos , Ácidos Grasos , Ácido Fólico , Antibacterianos/síntesis química , Antibacterianos/química , Antibacterianos/farmacología , Antivirales/síntesis química , Antivirales/química , Antivirales/farmacología , Células Cultivadas , Curcumina/análogos & derivados , Curcumina/síntesis química , Curcumina/farmacología , Dipéptidos/síntesis química , Dipéptidos/química , Ácidos Grasos/síntesis química , Ácidos Grasos/química , Ácido Fólico/síntesis química , Ácido Fólico/química , VIH-1/efectos de los fármacos , Humanos , Pruebas de Sensibilidad Microbiana , Estructura MolecularRESUMEN
Thymidine phosphorylase (TP) is a catabolic enzyme in thymidine metabolism that is frequently upregulated in many solid tumors. Elevated TP levels are associated with tumor angiogenesis, metastasis and poor prognosis. Therefore, the use of TP inhibitors might offer a promising strategy for cancer treatment. The tritylated inosine derivative 5'-O-tritylinosine (previously designated KIN59) is a non-competitive inhibitor of TP which was previously found to be instrumental for the crystallization of human TP. A combination of computational studies including normal mode analysis, automated ligand docking and molecular dynamics simulations were performed to define a plausible binding site for 5'-O-tritylinosine on human TP. A cavity in which 5'-O-tritylinosine could fit was identified in the vicinity of the Gly405-Val419 loop at a distance of about 11A from the substrate-binding site. In the X-ray crystal structure, this pocket is characterized by an intricate hydrogen-bonding network in which Asp203 was found to play an important role to afford the loop stabilization that is required for efficient enzyme catalysis. Site-directed mutagenesis of this amino acid residue afforded a mutant enzyme with a severely compromised catalytic efficiency (V(max)/K(m) of mutant enzyme approximately 50-fold lower than for wild-type TP) and pronounced resistance to the inhibitory effect of 5'-O-tritylinosine. In contrast, the D203A mutant enzyme kept full sensitivity to the competitive inhibitors 6-aminothymine and 6-amino-5-bromouracil, which is in line with the kinetic properties of these inhibitors. Our findings reveal the existence of a previously unrecognized site in TP that can be targeted by small molecules to inhibit the catalytic activity of TP.
Asunto(s)
Ácido Aspártico/metabolismo , Inhibidores Enzimáticos/farmacología , Inosina/análogos & derivados , Timidina Fosforilasa/metabolismo , Compuestos de Tritilo/farmacología , Secuencia de Aminoácidos , Animales , Ácido Aspártico/antagonistas & inhibidores , Dominio Catalítico , Cristalización , Cristalografía por Rayos X , Humanos , Enlace de Hidrógeno , Inosina/farmacología , Cinética , Modelos Moleculares , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Homología de Secuencia de Aminoácido , Timidina Fosforilasa/antagonistas & inhibidores , Timidina Fosforilasa/química , Timidina Fosforilasa/genéticaRESUMEN
The target phosphoramidates 5a-e were prepared in one step from 3-hydroxypropyl derivatives 3a-e of nonsteroidal anti-inflammatory drugs (fenoprofen, ketoprofen, ibuprofen, indomethacin, diclofenac). The products 3a-e and 5a-e were evaluated for their cytostatic and antiviral activity against malignant tumour cell lines and normal human fibroblasts (WI 38). All phosphoramidate derivatives 5a-e possess significantly greater inhibitory activities than the corresponding 3-hydroxypropyl derivatives 3a-e, whereby compound 5a showed the most potent inhibitory activities against cervical, pancreatic and colon carcinoma cell lines (IC(50)=5-7 microM).
Asunto(s)
Amidas/síntesis química , Antiinflamatorios no Esteroideos/síntesis química , Antineoplásicos/síntesis química , Ácidos Fosfóricos/síntesis química , Amidas/farmacología , Antiinflamatorios no Esteroideos/farmacología , Antineoplásicos/farmacología , Antivirales , Línea Celular , Línea Celular Tumoral , Citostáticos/síntesis química , Fibroblastos , Humanos , Concentración 50 Inhibidora , Ácidos Fosfóricos/farmacología , Relación Estructura-ActividadRESUMEN
Nucleoside analogs are widely applied in antiviral and antitumor therapy. A severe limitation of these compounds arises from the need of biotransformation to the eventually active nucleoside triphosphates by stepwise addition of phosphate by kinases. This problem can be circumvented by employing reversibly masked nucleotides (prodrugs). However, the known concepts to bypass enzyme activation have almost exclusively been applied to nucleoside monophosphates. Here, we report on the transfer of the bis-(acyloxybenzyl)-concept (BAB-concept) from nucleoside monophosphates to nucleoside diphosphates (NDP) of the anti HIV drugs AZT and d4T. After successful synthesis and isolation of the compounds (BAB-NDPs), it was shown that these compounds exhibit promising hydrolytic properties ranging from high stability at physiological pH to very low stability in cellular extracts. Furthermore, we demonstrated that for some of the compounds a selective cleavage mechanism resulted in the exclusive delivery of the corresponding nucleoside diphosphate within 15 minutes without any degradation of the pyrophosphate unit, which is a unique result in the field of NDP-prodrugs.
Asunto(s)
Fármacos Anti-VIH/química , Difosfatos/química , Nucleósidos/química , Profármacos/química , Fármacos Anti-VIH/metabolismo , Hidrólisis , Nucleósidos/metabolismo , Profármacos/metabolismo , Nucleótidos de Timina/química , Nucleótidos de Timina/metabolismo , Zidovudina/análogos & derivados , Zidovudina/química , Zidovudina/metabolismoRESUMEN
A dideoxythymidine analog, viz. 3'-N, N-dimethyl-2'-3'-dideoxythymidine (3) and its 5'-O-carboxyl ester prodrug derivatives (4-6) have been synthesized as probable antiviral agents. All these compounds have shown low to moderate level of antiviral activities against HIV, HSV 1 & 2, reovirus and many others.
Asunto(s)
Antivirales/síntesis química , Didesoxinucleótidos/síntesis química , Didesoxinucleótidos/farmacología , Animales , Antivirales/química , Antivirales/farmacología , Línea Celular , Didesoxinucleótidos/química , Humanos , Profármacos/síntesis química , Profármacos/químicaRESUMEN
A number of curcumin bioconjugates with fatty acid, dipeptide and folic acid, viz. di-O-decanoyl curcumin (2), di-O-tryptophanylphenylalanine curcumin (3), di-O-bis-(gamma, gamma)folyl curcumin (4), C(4)-ehyl-O-gamma-folyl curcumin (5) and 4-O-ethyl-O-gamma-folyl curcumin (6) have been synthesized. Conjugates 2-6 have shown good antiviral property with EC(50) ranging between 0.019-0.105 microM against a wide range of viruses, like HIV, HSV, VSV and many others.
Asunto(s)
Antivirales/síntesis química , Curcumina/análogos & derivados , Antivirales/metabolismo , Antivirales/farmacología , Curcumina/metabolismo , Curcumina/farmacología , Diseño de FármacosRESUMEN
Increased 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG) uptake is the most commonly used marker for positron emission tomography in oncology. However, a proliferation tracer such as 3'-deoxy-3'-[18F]fluorothymidine (FLT) might be more specific for cancer. 3'-deoxy-3'-[18F]fluorothymidine uptake is dependent on thymidine kinase 1 (TK) activity, but the effects of chemotherapeutic agents are unknown. The aim of this study was to characterise FDG and FLT uptake mechanisms in vitro before and after exposure to chemotherapeutic agents. The effects of 5-fluorouracil (5-FU), doxorubicin and paclitaxel on FDG and FLT uptake were measured in MDA MB231 human breast cancer cells in relation to cell cycle distribution, expression and enzyme activity of TK-1. At IC50 concentrations, 5-FU resulted in accumulation in the G1 phase, but doxorubicin and paclitaxel induced a G2/M accumulation. Compared with untreated cells, 5-FU and doxorubicin increased TK-1 levels by >300. At 72 h, 5-FU decreased FDG uptake by 50% and FLT uptake by 54%, whereas doxorubicin increased FDG and FLT uptake by 71 and 173%, respectively. Paclitaxel increased FDG uptake with >100% after 48 h, whereas FLT uptake hardly changed. In conclusion, various chemotherapeutic agents, commonly used in the treatment of breast cancer, have different effects on the time course of uptake of both FDG and FLT in vitro. This might have implications for interpretation of clinical findings.
Asunto(s)
Antineoplásicos/farmacología , Neoplasias de la Mama/metabolismo , Doxorrubicina/farmacología , Fluorodesoxiglucosa F18/metabolismo , Fluorouracilo/farmacología , Paclitaxel/farmacología , Timidina/metabolismo , Neoplasias de la Mama/enzimología , Neoplasias de la Mama/patología , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Humanos , Timidina Quinasa/metabolismoRESUMEN
Incubation of cells with thymidine (dThd) is known to cause dNTP pool imbalance as well as deletions and depletion of the mtDNA. In order to gain further understanding in the events involved in dThd toxicity over time, H9 cells were cultured for 20 months in the presence or absence of 1 micro M dThd. The level of mtDNA was reduced by 90% in the cells grown in dThd as compared to the control cells. The H9/dThd cells also showed a 100-fold increased sensitivity towards the cytotoxicity of the antileukemic compound 9-beta-D-arabinofuranolsylguanine (araG).